Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
ALK-negative anaplastic large cell lymphoma (ALK- ALCL) is a type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the lack of expression of a protein called anaplastic lymphoma kinase (ALK).
Biomarker and diagnostic research for ALK-negative anaplastic large cell lymphoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for ALK-negative anaplastic large cell lymphoma.
90 publications have been identified in PubMed for ALK-negative anaplastic large cell lymphoma. Kisho has analyzed 60 by research type. Research spans Case Report / Case Series (43%), Basic Science / Preclinical (20%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 26 | 43% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:06 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ALK-negative anaplastic large cell lymphoma
Laboratory research |
12 |
20% |
Research summaries | 6 | 10% |
Disease patterns and progression | 6 | 10% |
Other research | 3 | 5% |
Clinical study results | 3 | 5% |
Testing and diagnosis research | 2 | 3% |
New treatment approaches | 2 | 3% |
Kaseb H (2026). [PMID: 30725835](https://pubmed.ncbi.nlm.nih.gov/30725835/). *Unknown Journal*. [Basic Science / Preclinical]
Feldman AL (2026). [PMID: 41329859](https://pubmed.ncbi.nlm.nih.gov/41329859/). *Blood*. [Basic Science / Preclinical]
Vickery J (2026). [PMID: 41957230](https://pubmed.ncbi.nlm.nih.gov/41957230/). *Ann Hematol*. [Basic Science / Preclinical]
Satomi H (2026). [PMID: 41391855](https://pubmed.ncbi.nlm.nih.gov/41391855/). *J Clin Exp Hematop*. [Case Report / Case Series]
Zhang J (2026). [PMID: 41632580](https://pubmed.ncbi.nlm.nih.gov/41632580/). *Clin Nucl Med*. [Case Report / Case Series]
Unknown (2026). [PMID: 41885847](https://pubmed.ncbi.nlm.nih.gov/41885847/). *Blood*. [Other]
Suzuki K (2026). [PMID: 41798672](https://pubmed.ncbi.nlm.nih.gov/41798672/). *Radiol Case Rep*. [Case Report / Case Series]
Zhao F (2026). [PMID: 41787808](https://pubmed.ncbi.nlm.nih.gov/41787808/). *Intern Med J*. [Other]
Ozsen M (2026). [PMID: 42168142](https://pubmed.ncbi.nlm.nih.gov/42168142/). *Int J Surg Pathol*. [Case Report / Case Series]
Shyamsundar S (2026). [PMID: 41836733](https://pubmed.ncbi.nlm.nih.gov/41836733/). *Curr Probl Cancer Case Rep*. [Case Report / Case Series]